May, 06 2024

Thermo Fisher Scientific Inc., Illumina Inc. and Ge Healthcare Are Dominated the Market for Global Cancer Diagnostics Market In 2016

Global Cancer Diagnostics Market is expected to reach USD 40.10 billion by 2024 from USD 16.55 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Cancer diagnostics market has the largest market segment in drug delivery market.

Access Full Report: https://www.databridgemarketresearch.com/reports/global-cancer-diagnostics-market

The global cancer diagnostics market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Thermo Fisher Scientific, Inc. dominated the cancer diagnostics market, by platform based accounting for the highest market share in 2016, followed by Illumina, Inc. and Roche Diagnostics. GE Healthcare dominated the cancer diagnostics market, by imaging accounting for the highest market share in 2016, followed by Siemens Healthcare GmbH and Hologic, Inc. Other players in this market include Agilent Technologies, Abbott, Becton, Dickinson and Company, and Koninklijke Philips N.V., among others holds 24.7% of the global cancer diagnostics market in 2016.

Thermo Fisher Scientific Inc,:

Founded in 2006 as Thermo Fisher Scientific, Inc, and head quartered in Massachusetts, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through four business segments: laboratory products and services, life sciences and solutions, analytical instruments and specialty diagnostic.

Recent Developments:

In June 2017, Thermo Fisher Scientific Inc. established a partnership with the Institute Of Medical Genetics and Pathology at University Hospital Basel.

In March 2017, Thermo Fisher Scientific Inc. introduced the QuantStudio 5 Real-Time PCR System, designed to use with HID real time PCR analysis that optimises the use by reducing the cost and increasing efficiency.

Illumina Inc.:

Founded in 1998 and headquartered in San Diego, USA. Illumina, inc. is engaged in the development, manufacturing and market integration for analysis of genetic variation and biological function. The company operates through three business segments, namely research, applied science and clinical. The research segment includes the Molecular Biological research tool, Applied Genomics Solutions, Oncology, Microbial Genomics and Genomics in Drug Development. The Applied Science segment of company offers Forensic Genomics, Commercial Agricultural Applications, Molecular Epidemiology and Biobank Analysis Solution. The clinical segment includes Molecular Diagnostics, Reproductive and Genetic Health, Translational Research and others.

Recent Developments:

In June 2017, Illumina Inc. announced the FDA approval of Extended RAS Panel for the evaluation of colorectal cancer from the American Cancer Society for Clinical Pathology (ASCP).

In April 2017, Illumina Inc. reported the launch of the VeriSeq NIPT solution, based on CE-IVD marked next-generation sequencing (NGS) approach for the non invasive pre-natal testing (NIPT), also including CE-IVD marked library prep and analysis software.

GE Healthcare:

Founded in 1994 and headquartered in Chicago, U.S. GE Healthcare provides transformational medical technologies and services. GE healthcare operates through three business segments healthcare systems, life sciences, and healthcare digital.

Recent Developments:

In March 2017, GE Healthcare introduced its latest product positron emission tomography/ computed tomography IQ PET/CT in Egypt for early detection of cancer and track patient’s responses to cancer treatment.

In March 2017, GE Healthcare launched Clariscan (gadoteric acid) at the European Congress of Radiology (ECR) meeting in Europe to detect abnormalities in the brain, spine and associated tissues.

Simens Healthcare GmbH:

Founded in 1847 and headquartered in Erlangen, Germany. Siemens Healthcare GmbH is engaged in medical technologies. The company operates through different business segments, such as medical imaging, laboratory diagnostic, point of care testing, healthcare IT services, and clinical specialities & diseases. The clinical specialties & diseases segment includes cardiology, neurology, oncology, surgery, women health and others. In oncology, Siemens Healthcare GmbH provides Imaging, Laboratory Diagnostics, Virtual MR/Ultrasound Guidance for TRUS Assisted Prostate Biopsy and others.

Recent Developments:

In May 2016, Siemens Healthcare GmbH acquired NEO New Oncology AG. With this acquisition Siemens Healthcare will expand its portfolio with molecular testing related services and technologies for oncology and genomics

CHOOSE LICENCE TYPE

Enterprise User 7000
Single User 4800
DBMR Factbook 3000
DBMR Prime 8000
DBMR Supreme 12000

Buy Now

Advance Formative Research Customization Request for bulk Reports

Latest Press Release

Growth in Offshore Oil and Gas Activities is driving the Growth of the U.S Ship Repair and Maintenance Services Market

Rising Prevalence of Genetic Disorders is Driving the Growth of the Global Multiple Hereditary Exostosis Market

Growing Industrialization Fuels Lubricant Usage in Machinery and Equipment is Expected to Drive the Growth for the U.S. Lubricants Market

Rising Demand for Quality Control is Driving the Growth of the Global Industrial Metrology Market

Increasing Prevalence Of Hepatitis B Infections Drives the Growth of Global Hepatitis B Treatment Market

VIEW ALL

Client Testimonials

David Manning - Thermo Fisher Scientific

Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Manager - Market Analytics,

Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,

(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Business Intelligence and Analytics,

Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst,

Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director,

Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,

A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director,

Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager,

Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations,

GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst,

Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager,

Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment

MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer

Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro

Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)

UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future

Press Release